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Abstract 
Extracellular vesicles (EVs) are implicated in the pathogenesis of cardiovascular disease (CVD). 
Specifically, platelet-derived EVs are highly pro-coagulant, promoting thrombin generation and fibrin 
clot formation. Nitrate supplementation exerts beneficial effects in CVD, via an increase in nitric oxide 
(NO) bioavailability. Clopidogrel is capable of producing NO-donating compounds, such as S-
nitrosothiols (RSNO) in the presence of nitrite and low pH. The aimof this studywas to assess the 
effect of nitrate supplementationwithversus without clopidogrel therapy on circulating EVs in coronary 
artery disease (CAD) patients. In this randomized, double-blind, placebo-controlled study, CAD 
patients with (n ¼ 10) or without (n ¼ 10) clopidogrel therapy received a dietary nitrate supplement 
(SiS nitrate gel) or identical placebo. NO metabolites and platelet activation were measured using 
ozonebased chemiluminescence and multiple electrode aggregometry. EV concentration and origin 
were determined using nanoparticle tracking analysis and time-resolved fluorescence. Following 
nitrate supplementation, plasma RSNO was elevated (4.7 _ 0.8 vs 0.2 _ 0.5 nM) and thrombin-
receptor mediated platelet aggregation was reduced (_19.9 _ 6.0 vs 4.0 _ 6.4 U) only in the 
clopidogrel group compared with placebo. Circulating EVs were significantly reduced in this group 
(_1.183e11 _ 3.15e10 vs_9.93e9 _ 1.84e10 EVs/mL), specifically the proportion of CD41þ EVs 
(_2,120 _ 728 vs 235 _ 436 RFU [relative fluorescence unit]) compared with placebo. In vitro 
experiments demonstrated clopidogrel–SNO can reduce platelet-EV directly (6.209e10 _ 4.074e9 vs 
3.94e11 _ 1.91e10 EVs/mL). In conclusion, nitrate supplementation reduces plateletderived EVs in 
CAD patients on clopidogrel therapy, increasing patient responsiveness to clopidogrel. Nitrate 
supplementation may represent a novel approach to moderating the risk of thrombus formation in 
CAD patients. 
 
Introduction 
Extracellular vesicles (EVs) are small, spherical structures (0.1–1-μm diameter) enclosedwithin a 
phospholipid bilayer, generated by multiple cell types including platelets, leukocytes and endothelial 
cells. EVs represent a novel way of communication between cells, transporting both protein and 
genetic material. Recently, EVs have been implicated as a potential biomarker of cardiovascular 
disease (CVD), and are considered to play a crucial role in the promotion of coagulation, 1 
inflammation2 and cell survival.3 Elevated levels of EVs have been observed in a range of CVD 
states,4 and have been shown to correlate with poor outcomes in coronary artery disease (CAD) 
patients.5 Therefore, EVs represent an attractive target for pharmacological and/or dietary 
intervention. 
Platelet-derived EVs have received the most attention in the field, primarily due to their abundance 
and reactivity.6 The surface of platelet-derived EVs is approximately 100-fold more pro-coagulant 
than the surface of activated platelets themselves.7 Platelet-derived EVs express phosphatidylserine 
that stimulates thrombin generation and stabilizes fibrin clot formation.1 Therefore, a method of 
reducing platelet-EVs might be of clinical benefit in CVD patients. Thienopyridines, such as 
clopidogrel, act via irreversible inhibition of the adenosine diphosphate (ADP) receptor, preventing 
platelet activation. In addition to their antiplatelet actions, additional properties have been reported, 
particularly with clopidogrel, including improvement in nitric oxide (NO) bioavailability, anti 
inflammatory effects and reduced endothelial injury after percutaneous coronary intervention (PCI).8 
Previous studies have shown that clopidogrel reduces EV production in parallel with suppression of 
platelet activation in patients with acute coronary syndromes (ACSs).9 NO plays an essential role in 
maintaining both endothelial and platelet homeostasis; however, NO levels are compromised in CVD, 
resulting in the progression of atherosclerosis and vascular dysfunction.10 In platelet physiology, NO, 
acting via the cyclic guanosine monophosphate (cGMP) pathway, offers an additional inhibitory 
pathway to thienopyridine mediated inhibition. When activated together, ex vivo studies have shown 
that they produce a synergistic anti-platelet effect, culminating in a reduction in intracellular 
calcium.11 Ingestion of dietary nitrate elevates circulating levels of nitrite via bioconversion by 
commensal bacteria in the enterosalivary circulation.12 The benefits of nitrate supplementation in 
CVD are well documented; it has recently been shown to improve vascular function in 
hypercholesterolemia patients, and reduce ex vivo platelet aggregation in response to 
ADP/collagen.13,14 Additionally, Lee et al have recently shown that sustained-release nitrates can 
act synergistically with clopidogrel to enhance platelet inhibition in patients undergoing PCIs.15 S-
nitrosothiols (RSNO) are a class of compound formed by S-nitrosation of reduced sulphydryl groups, 
and are able to act as NO donors, with potent anti-platelet effects.16 Our group has previously 
demonstrated that thienopyridines readily form RSNO,17 dependent on a low pH and nitrite(NO2_) 
availability, both of which are present in the stomach. These thienopyridine–SNO molecules are able 
to mimic NO with the additional benefit that the NO “moiety” is protected and preserved from further 
reactive metabolism. We hypothesized that inorganic nitrate supplementation with clopidogrel therapy 
would increase plasma RSNO levels and subsequently reduce circulating EVs in CAD patients. 
 
Methods 
Subjects and Protocol 
Twenty patients with established CAD volunteered and consented to take part in this proof-of-
concept, randomized, double-blind, placebo-controlled, crossover study. Patients were split into those 
receiving clopidogrel 75 mg daily (n ¼ 10) and those receiving no anti-platelet therapy, referred to 
henceforth as “naïve” (n ¼ 10). Patients attended the Cardiology Day Case Unit, University Hospital 
of Wales (UHW), as part of their normal clinical care. All patients were randomized to receive either 2 
_ 60 mL (67.2 mM, confirmed by ozone-based chemiluminescence) of dietary nitrate supplement 
(Science in Sport GoþNitrates), followed by a placebo (of identical appearance), or vice versa. We 
have previously shown that from ingestion of this dose of inorganic nitrate, plasma nitrate and nitrite 
values peak at 2 hours and have returned to baseline within 24 hours.18  We adopted a washout 
period of 7 days, in agreement with several other groups.19,20 ►Fig. 1 summarizes the study design. 
Blood samples were taken from the antecubital vein through an 18-g Venflon intravenous (IV) cannula 
into EDTA (ethylenediaminetetraacetic acid), citrate and hirudin vacutainers. Samples were taken 
both before ingestion ingestion of the supplement and 2 hours post-supplementation. Patients took all 
prescribed medication at least 1 hour prior to the study. Patients were included if they were male, over 
18 years of age with stable CAD and had been fasted for >6 hours. Patients in the clopidogrel group 
must have been receiving clopidogrel for >1 month prior to commencement of the study. Patients 
were excluded if they had a clopidogrel intolerance or contraindication, were on other long-term oral 
anti-coagulant drugs or receiving IV or subcutaneous anti-thrombin therapy. Patients were also 
excluded if they had any ischemic event (ACS, stroke or transient ischemic attack) or 
revascularization procedure (PCI or CABG) within the preceding 3 months, chronic renal or liver 
disease, or an inability to give informed consent. This study conformed to the ethical principles 
contained in the Declaration of Helsinki. Ethical approval was provided by the South East Wales 
Research Ethics Committee (IRAS Project ID 102427). 
 
Biochemical Measurements 
A full blood count was measured on an ABX Pentra X120 
A full blood count was measured on an ABX Pentra X120 haematology blood analyser (Horiba, 
Northampton, UK). Serum cholesterol, high-density lipoprotein cholesterol and triglycerides were 
assessed using an Aeroset automated analyser (Abbott Diagnostics, Berkshire, UK). Low-density 
lipoprotein cholesterol was calculated using Friedewald’s formula. C-reactive protein was assayed by 
nephelometry (BN-II system, Milton Keynes, UK). All biochemical measurements were performed by 
the Department of Medical Biochemistry,UHW. 
 
 
 
 
 
Measurement of Plasma NO Metabolites 
Blood samples were collected into EDTA vacutainers and promptly centrifuged (2,500g, 15 minutes, 
4°C) to yield plasma which was subsequently snap frozen in liquid nitrogen and stored at _80°C until 
analysis. NO metabolites were assessed using ozone-based chemiluminescence. Briefly, for 
plasma nitrite and RSNO analysis, 5-mL tri-iodide reagent (I3 _) was placed in a custom-built glass 
purge vessel and heated at 55°C via a water bath thermostatically controlled by a hotplate. The inert 
carrier gas (O2-free N2) purging I3 _ was linked to a sodium hydroxide trap (1 M), connected to an 
NOanalyser (Sievers NOA 280i; Analytix, Boldon, UK). Plasma samples (200 μL nitrite, 400 μL 
RSNO) were directly injected in to the purge vessel through a rubber septum injection inlet. To 
differentiate between nitrite and RSNO, samples were run before and after pre-treatment with 5% 
acidified sulphanilamide (290 mM), which removes NO2 _, thus allowing the selective measurement 
of the residual plasma RSNO. Increased accuracy of RSNO measurement was obtained by a 50-point 
adjacent signal averaging algorithm, improving the signal-to-noise ratio, using Origin 7.0 (OriginLab, 
Massachusetts). For nitrate analysis, plasma samples (20 μL) were injected into vanadium chloride 
heated at 90°C before detection via the NO analyser. Results were compared with a sodium 
nitrite/nitrate standard curve performed daily to account for day-to-day temperature fluctuations. 
Room temperature was 19 _ 2°C. In our hands, the limit of sensitivity for these plasma RSNO, nitrite 
and nitrate assays are >1, >10 and >500 nmol/L, respectively. 
 
Platelet Aggregation 
Whole blood aggregation was assessed via multiple electrode aggregometry, using the Multiplate 
analyser (Roche Diagnostics, Forrenstrasse, Switzerland). The adhesion and aggregation of platelets 
on the sensor surface enhances the electrical resistance between the two sensor electrodes within a 
test cell.Whole blood (300 μL) collected in a hirudin vacutainer was diluted 1:1 with saline solution and 
incubated at 37°C for 3minutes andmeasuredwithin 30minutes of blood drawing. Following this, 
platelet activation was initiated by the addition of either ADP (6.5 μM) or thrombin receptor-activating 
peptide (TRAP; 32 μM). The subsequent increase in impedance due to attachment of platelets to the 
electrodes is transformed to arbitrary aggregation units. The aggregation measured is quantified as 
the area under thecurve (AUC) and expressed in units (U). 
 
Extracellular Vesicle Isolation 
Blood was collected into sodium citrate vacutainers, as recommended by the Scientific 
Standardisation Committee of the International Society on Thrombosis andHaemostasis.21,22 
Blood was immediately centrifuged (2,500g, 15 minutes, 4°C)to isolate plasma, which was 
subsequently spun (2,500g,15 minutes, 4°C) to obtain platelet-poor plasma (PPP). PPP was 
ultracentrifuged (100,000g, 60 minutes, 4°C) and the resulting EV pellet was resuspended in 
phosphate-buffered saline (PBS) and slow-frozen overnight at _80°C. All EV analysis was completed 
within 7 days of isolation. This is an established protocol that we have utilized in several clinical 
studies to date.23–25EV Size and Concentratio nEV concentration and size distribution were 
determined using nanoparticle tracking analysis (NTA; NanoSight LM10 system, UK) as described 
previously. NTA is a laser-illuminated microscopic technique equipped with a 642-nmlaser and a high-
sensitivity digital camera system (Orca-Flash2.8, Hamamatsu, NanoSight Ltd) that determines the 
brownian motion of nanoparticles in real time to assess sizea nd concentration. Sixty-second videos 
were recorded and particle movement was analysed using NTA software (version 2.3). Camera 
sensitivity and detection threshold were 11 to 14 and 4 to 6, respectively. EV samples were diluted in 
EV-free sterile PBS. Samples were run in quintuplicate, from which EV distribution, size and average 
concentration were calculated. EV concentrations were expressed as EVs/mL plasma. 
 
EV Cellular Origin 
Time-resolved fluorescence was used to assess the origin of isolated EVs, as described previously.23 
EVs (5e10/well) were loaded into a high protein binding 96-well plate (Greiner Bio-One, Germany) 
overnight at 4°C, before non-specific sites were blocked with 1% bovine serum albumin for 
2 hours. EVs were incubated overnight at 4°C with mouse anti-human antibodies against CD9, CD41, 
CD11b, CD235a and CD144 as markers of exosomes, platelets, leukocytes, erythrocytes and 
endothelial cells, respectively (all antibodies from Abcam, Cambridge, UK). Markers were detected 
using a biotinylated anti-mouse IgG secondary antibody and a streptavidin:europium conjugate 
(PerkinElmer, Buckinghamshire, UK). 
 
In Vitro Platelet EV Production 
The in vitro model was designed to confirm the capability of clopidogrel–SNO to inhibit platelet EV 
release in response to a pharmacological stimulus (ADP). Platelet-rich plasma (PRP) was isolated 
from the blood of healthy volunteers via sodium citrate vacutainers (200g, 20 minutes). PPP was also 
isolated (200g, 20 minutes, followed by 2 _ 2,500g, 15 minutes) for use as a control. Platelets were 
stimulated with ADP (6.5 μM) and incubated for 5 minutes before NaNO2, clopidogrel, S-
nitrosoglutathione (GSNO) or clopidogrel–SNO (all 10 μM) were added and incubated for 1 hour at 
37°C. This concentration was chosen to compare directly with in vitro aggregation studies in healthy 
blood showing the IC50 for GSNO/ clopidogrel–SNO as approximately 7.5 μM. Clopidogrel–SNO was 
produced as described in detail previously by our group.17 
 
Statistics 
A power calculation based on prior results from EV samples from CAD patients showed that nine 
subjects would provide 90% power for detecting a 20% difference in circulating EVs between placebo 
and nitrate supplementation, assuming10% variation, with α ¼ 0.05. Data were analysed using 
GraphPad Prism version 5.0. Data are expressed as mean _ standard error (SE). All data were 
assessed for both a period effect and treatment–period interaction and checked for normality using 
the Kolmogorov–Smirnov test. The change in measurement before and after nitrate supplementation 
or placebo was calculated and compared directly using a paired t-test or a Wilcoxon matched pairs 
test, for normally or non-normally distributed data, respectively. 
 
Results 
Subject Characteristics 
Of the 20males that participated in the study, 10were taking clopidogrel (>1 month) and 10 were not 
receiving antiplatelet therapy (naïve group). The mean ages of the groups were 63.2 _ 3.6 and 62.7 _ 
3.2 years, respectively. Biochemical measurements are summarized in ►Table 1. Importantly, no 
differences were observed in platelet count at baseline or at the follow-up visit. No differences were 
seen in age, body mass index, biochemical or haematological parameters between groups. No 
significant period effects and treatment–period interaction were observed for any of 
the parameters determined in this study. 
 
Plasma NO Metabolites 
Baseline plasma nitrate, nitrite and RSNO measurements were not significantly different between 
naïve and clopidogrel groups (nitrate [NO3 _]: 31.14 _ 2.5 vs 31.34 _ 5.1 μM; NO2 _: 
92.3 _ 9.0 vs 118.9 _ 15.7 nM; RSNO: 6.4 _ 0.5 nM vs 11.9 _ 3.4 μM). Nitrate supplementation 
significantly elevated plasma NO3 _ and NO2 _ compared with placebo in both naïve 
(ΔNO3 _: 252.1 _ 17.4 μM vs 3.7 _ 1.9 μM, p < 0.001; ΔNO2 _: 
167.8 _ 40.1 vs 18.5 _ 22.6 nM, p < 0.05) (►Fig. 2a,c) and clopidogrel (ΔNO3 _: 256.6 _ 20.5 vs_2.0 
_ 3.4 μM, p < 0.001; ΔNO2 _: 164.8 _ 68.5 vs _5.2 _ 12.2 nM, p < 0.05) (►Fig. 2b, d) groups. 
Increases in plasma nitrate and nitrite were similar between naïve and clopidogrel groups (ΔNO3 
_naïve: 252.1 _ 17.4 μM vs clopidogrel: 256.6 _ 20.5 μM, p > 0.05; ΔNO2 _: naïve: 167.8 _ 40.1 nM 
vs clopidogrel: 164.8 _ 68.5 nM, p > 0.05). Plasma RSNO did not change following nitrate 
supplementation compared with placebo in the naïve group (ΔRSNO: 0.9 _ 1.3 vs _1.3 _ 0.6 nM) 
(►Fig. 2e). However, plasma RSNO was significantly elevated after receiving nitrate supplementation 
when compared with placebo in the clopidogrel group (ΔRSNO: 4.7 _ 0.8 vs 0.2 _ 0.5 nM, p < 0.001) 
(►Fig. 2f). Additionally, RSNO in the clopidogrel group was significantly elevated in comparison to 
the naïve group (4.7 _ 0.8 vs 0.9 _ 1.3 nM, p < 0.05), respectively. 
 
Platelet Aggregation 
TRAP-mediated platelet aggregation was not significantly different between clopidogrel and naïve 
groups (94.8 _ 7.0 vs 99.0 _ 6.3 U, respectively). Patients receiving clopidogrel had markedly lower 
ADP-mediated platelet aggregation compared with the naïve group at baseline (37.9 _ 3.80 vs 
60.0 _ 4.4 U, p < 0.001). Nitrate supplementation failed to significantly reduce both ADP- and TRAP-
mediated platelet aggregation in the naïve group when compared with placebo (ΔADP: _7.8 _ 5.8 vs 
2.1 _ 4.9 U, ΔTRAP: _21.5 _ 8.4 vs _3.8 _ 9.2 U) (►Fig. 3a). Nitrate supplementation had no effect 
on ADP-mediated platelet aggregation compared with placebo in patients receiving clopidogrel 
(ΔADP: _2.2 _ 2.2 vs 0.1 _ 1.8 U) (►Fig. 3b). However, nitrate supplementation did significantly 
reduce TRAP-mediated platelet aggregation in the clopidogrel group compared with placebo (ΔTRAP: 
_19.9 _ 6.0 vs 4.0 _ 6.4 U, p < 0.05) (►Fig. 3b). The reduction in ADP- and TRAP-mediated 
aggregation was similar within both the naïve and clopidogrel groups (ΔADP: naïve: _7.8 _ 5.8 U vs 
clopidogrel: _2.2 _ 2.2 U, p > 0.05. ΔTRAP: naïve: _21.5 _ 8.4 U vs clopidogrel: _19.9 _ 6.0 U, p > 
0.05). 
 
Table 1 Participant characteristics 
 
Abbreviations: ACEi/ARB, angiotensin converting enzyme inhibitors/angiotensin II receptor blocker; 
BMI, body mass index; CABG, coronary artery bypass grafting; COPD, chronic obstructive pulmonary 
disease; CRP, C-reactive protein; GTN, glyceryl trinitrate; HDL, high-density lipoprotein;LDL, low-
density lipoprotein; MI, myocardial infarction; NSAIDs, non-steroidal anti-inﬂammatory drugs; TIA, 
transient ischemic attack. 
Note: Summary of patient characteristics including age, BMI, SHIM score, cardiovascular risk factors, 
medications, biochemical and haematological measurements. Haematological measures were taken 
at the beginning of both patient visits, prior to any treatment. No statistically signiﬁcant differences 
between the two groups were observed (p > 0.05). 
 
 
Fig. 2 NO metabolite measurements. Thechangein plasmaNO metabolites 2 hours post-nitrate 
supplementation or placebo. (a) Naïve group plasma NO3�,µM. (b) Clopidogrel group plasma 
NO3�,µM. (c)Naïve group NO2�,nM. (d) Clopidogrel group plasma NO2�,nM. (e) Naïve group 
plasma RSNO, nM. (f) Clopidogrel group plasma RSNO, nM. Data are expressed as mean � SEM (n 
¼ 10). p < 0.05 and ���p < 0.001 
 
 
 
Fig. 3 Platelet aggregation. ADP- and TRAP-induced platelet ag-gregation as measured by MEA 
(multiple electrode aggregometry).(a) Agonist response in the naïve group. (b)Agonistresponse inthe 
clopidogrel group. Data are expressed as mean � SEM (n ¼ 10). p < 0.05. 
 
 
 
EV Size and Concentration 
Nitrate supplementation had no effect on the mode size of EVs compared with placebo in both naïve 
(123 _ 9.2 vs 111 _ 7.3 nm) and clopidogrel (129 _ 11.4 vs 122 _ 16.2 nm) groups, respectively. EV 
concentration at baseline did not differ between naïve and clopidogrel groups, respectively (5.0e11 _ 
4.2e10 EVs/mL vs 4.7e11 _ 3.7e10 EVs/mL). ►Fig. 4a shows the size distribution profile of EVs in 
both the naïve and clopidogrel group at baseline, split into 50-nm bin sizes. Nitrate supplementation 
did not reduce the circulating EV concentration compared with placebo in the naïve group (ΔEVs: 
_2.78e10 _ 4.22e10 vs 1.76e10 _ 1.23e10 EVs/mL). However, nitrate supplementation did 
significantly reduce EV concentration in the clopidogrel group compared with placebo (ΔEVs: 
_1.183e11 _ 3.15e10 vs _9.93e9 _ 1.84e10 EVs/mL, p < 0.01) (►Fig. 4b). The reduction in 
circulating EV concentration was similar between naïve and clopidogrel groups (_2.78e10 _ 4.22e10 
vs _1.183e11 _ 3.15e10 EVs/mL, p > 0.05), respectively. 
 
EV Cellular Origin 
Comparison between the naïve and clopidogrel groups revealed that the clopidogrel group had 
significantly higher baseline levels of exosomal (CD9), platelet (CD41) and leukocyte (CD11b) 
markers compared with the naïve group 
 
 
 
Fig. 4 Circulating EV concentration. (a) Size distribution profile for EVs in both the naïve and 
clopidogrel group, split into 50-nm bin sizes. (b) Change in circulating plasma EVconcentration 2 
hours post-nitrate supplementation/placebo in naïve and clopidogrel groups determined by NTA 
(nanoparticle tracking analysis). Data are expressed as mean _ SEM (n ¼ 10). _p < 0.05. 
 
(CD9: 32,899 _ 1,303 vs 23,812 _ 1,891 RFU [relative fluorescence unit], p < 0.001; CD41: 15,753 _ 
1,372 vs 10,064 _ 705 RFU, p < 0.01; CD11b: 14,245 _ 1,512 vs 9,578 _ 1,250 RFU, p < 0.05) (►Fig. 
5a). No significant differences were seen in surface protein markers for exosomes, platelets, 
leukocytes, erythrocytes (CD235a) and endothelial cells (CD144) of EVs in the naïve group following 
nitrate supplementation compared with placebo (►Fig. 5b). CD41 was significantly reduced following 
nitrate supplementation compared with placebo in patients receiving clopidogrel (ΔCD41: _2,120 _ 
728 vs 235 _ 436 RFU, p < 0.05) (►Fig. 5c). Changes in surface marker levels were similar 
 
 
 
 
Fig. 5 Effect of nitrate supplementation on EV surface protein. The change in content of exosomes 
(CD9), platelet (CD41), leukocyte (CD11b), erythrocyte (CD235a) and endothelial (CD144) in plasma 
EVs after nitrate supplementation versus placebo. (a) Difference in baseline levels of protein 
expression between naïve and clopidogrel groups (n ¼ 10). (b) Change in protein expression after 
nitrate supplementation/placebo in the naïve group (n ¼ 10). (c) Change in protein content after 
nitrate supplementation/placebo in the clopidogrel group (n ¼ 10). Proteins were detected using a 
streptavidin– europium conjugate and measured using time-resolved fluorescence (relative 
fluorescence units [RFU]). Data are expressed as mean _ SEM. ___p < 0.001, __p < 0.01 and _p < 
0.05. between naïve and clopidogrel groups (CD9: _471 _ 625 vs _1,079 _ 744, CD41: _498 _ 423 vs 
_2,120 _ 728, CD11b: _1,053 _ 934 vs _877 _ 441, CD235a: _259 _ 230 vs _678 _ 354, CD144: 
_364 _ 354 vs _106 _ 336, p > 0.05 for all comparisons). 
 
In Vitro Experiments 
Laboratory experiments were undertaken to investigate the direct effect of nitrite, clopidogrel and 
clopidogrel–SNO separately on platelet activation and EV generation. EV generation was increased 
200% in response to addition of ADP. Following a dose–response, 10 μM of inhibitors (sodium nitrite, 
clopidogrel–SNO, GSNO) were added, which showed this concentration was effective at inhibiting 
platelet aggregation and thus platelet-derived EV release. Indeed, aggregation measured in response 
to ADP was significantly inhibited by both clopidogrel–SNO and GSNO, with a similar IC50 
(6.56 _ 1.08 vs 8.42 _ 1.35 μM). Nitrite alone was ineffective at inhibiting platelet aggregation in 
response to ADP unless concentrations greater than 10 mM were applied (►Fig. 6a). The addition of 
sodium nitrite (NaNO2) or clopidogrel to stimulated PRP had no effect on EV production (NaNO2: 
3.83e11 _ 1.707e10 EVs/mL, clopidogrel: 3.91e11 _ 1.805e10 EVs/mL, vs ADP alone as control 
3.94e11 _ 1.91e10 EVs/mL). Similarly, no change in CD41 was observed (NaNO2: 20,093 _ 
1,244 RFU, clopidogrel: 18,238 _ 2,824 RFU, vs ADP control: 19,703 _ 1,375 RFU, p > 0.05). 
Following the addition of clopidogrel–SNO, EV production significantly reduced compared with the 
ADP control (6.209e10 _ 4.074e9 vs 3.94e11 _ 1.91e10 EVs/mL, p < 0.001). GSNO also significantly 
reduced EV production compared with the ADP control (8.67e10 _ 8.63e9 EVs/mL, p < 0.001) (►Fig. 
6b). Reductions were also seen in CD41 expression following addition of both SNO molecules 
compared with control (GSNO: 8,946 _ 1,460 RFU, clopidogrel–SNO: 9,713 _ 1,214 RFU, vs ADP 
control: 19,703 _ 1,375 RFU, p < 0.01) (►Fig. 6c). 
 
Discussion 
This study shows that acute dietary NO3 _ supplementation significantly reduces circulating EVs in 
patients with CAD already established on long-term clopidogrel therapy. Furthermore, it significantly 
reduced platelet activation via the thrombin receptor, accompanied by a reduction in the proportion of 
platelet-derived EVs. This reduction was associated with a rise in circulating RSNO only in the 
clopidogrel group. Previously thought of as a physiologically inert oxidative end product of NO 
metabolism, it is now widely accepted that NO3 _ and NO2 _ metabolism occurs in both blood and 
tissues to form NO and other bioactive NO metabolites, representing an alternative to the “classical” 
L-arginine pathway. 12 NO3 _ supplementation has been shown to have a variety of benefits in CVD 
including improving vascular function,13 decreasing blood pressure26 and attenuating oxidative 
stress.27 
Baseline measurements of plasma NO2 _ prior to NO3 _ supplementation or placebo were noticeably 
lower in both the naïve (92.3 _ 9.0 nM) and clopidogrel (118.9 _ 15.7 nM) groups compared with the 
values typically observed in healthy individuals (200–300 nM) we have reported previously. 28 These 
low NO2 _ levels reflect the reduced NO bioavailability and degree of endothelial dysfunction seen in 
these patient cohorts. 
Significant elevations in plasma RSNO levels following NO3 _ supplementation were seen only in 
patients taking clopidogrel. We have previously demonstrated in vitro that the low pH environment of 
the stomach can modify thienopyridines, to form thienopyridine–SNO molecules29 that exhibit NO-like 
biological effects, including platelet inhibition and vasodilation.30,31 The low pH exposes the free thiol 
group present in these drugs, before biotransformation in the presence ofNO2 _ to form RSNO 
compounds. These molecules provide an addition to the nitrate–nitrite–NO pathway and the effects 
seen upon nitrate/nitrite supplementation.32  
Patients receiving proton-pump inhibitors (PPIs; and thus an increased pH in the stomach) exhibit 
reduced platelet inhibition in response to clopidogrel, although the mechanismof this is felt to be 
multifactorial and incompletelydefined.33 Recently, Pinheiro et al have shown that oralnitrite 
administration in rats was associated with an increase in RSNO and a decrease in blood pressure.34 
Furthermore, treatment with both PPIs and the thiol-depleting agent buthionine sulfoximine attenuated 
the increase in plasma RSNO and blunted the anti-hypertensive effects of nitrite.34 
 
 
 
 
Fig. 6 In vitro platelet EV production. (a) Dose–response curve of GSNO, clopidogrel–SNO and nitrite 
on platelet inhibition. The IC50 of GSNO 
and clopidogrel–SNO were similar (6.56 _ 1.08 vs 8.42 _ 1.35 μM). (b) The effect of various agents on 
EV production. Clopidogrel–SNO 
severely attenuated EV production in platelet-rich plasma. An alternative nitrosothiol, GSNO, also 
inhibited EV production. (c) The reduction in 
EV concentration was mirrored by a reduction in CD41 expression, measured by TRF. n ¼ 4, ___p < 
0.001 and __p < 0.01. 
 
 
However, the influence of stomach pH on RSNO formation inpatients is yet to be established. 
 
To our knowledge, this is the first study to demonstrate that dietary nitrate supplementation can 
reduce circulating EV concentration when administered with clopidogrel. The lack of RSNO produced 
in the naïve group and absence of a significant reduction in EV concentration suggest these effects 
are due to formation of clopidogrel–SNO molecules in the stomach. Conversely, in patients receiving 
clopidogrel and NO3_ clopidogrel–SNO is formed which can subsequently donate NO in the plasma 
as previously demonstrated.35 Our group have previously shown that nitrite-derived NO can reduce 
EV production in endothelial cells.36 This is consistent with previous reports that showed impairment 
of NO production increased EV production in endothelial cells.37 It is well established that NO elicits 
many of its effects, such as platelet activation, via a reduction in intracellular calcium. Conversely, 
many of the processes required for EV formation, such as lipid membrane remodelling and 
cytoskeleton disruption require increases in intracellular calcium.38 Our in vitro results confirm 
clopidogrel– SNO, derived from NO2 _, inhibits platelet EV generation directly, where NO2 _ and 
clopidogrel alone had no effect. This is consistent with inhibition of platelet aggregation we have 
observed at these concentrations and with previously established effects of RSNO on platelets.39 
 
Interestingly, a significant reduction in EV concentration was only seen in the clopidogrel group. 
Whether this decrease can be attributed to the increased RSNO levels seen compared with the naïve 
group, or as a result of the combination of two independent effects of NO and clopidogrel, remains 
unclear. Clopidogrel acts via inhibition of the ADP/ P2Y12 receptor, preventing the inhibition of 
adenylate cyclase, consequently reducing platelet aggregation. The ADP receptor has previously 
been shown to have a potentiating role in dense granule secretion.40 Granule and vesicle release 
from platelets is mediated by common cellular machinery such as SNARE proteins, intracellular 
calcium levels and cytoskeletal organization.41 Thus, it is possible that the reduction in plasma EV 
seen in our patient cohort could be due to the combined, independent effects of NO and clopidogrel. 
However, given our data showing a significant reduction of platelet EV seen when clopidogrel–SNO is 
administered in vitro, it seems likely that the increased formation of RSNO in these patients causes 
the reduction in EV seen in this study. 
 
Consistent with previous ex vivo studies, we provide evidence that nitrate supplementation can act 
synergistically with the P2Y12 inhibitor clopidogrel resulting in augmented platelet inhibition than 
clopidogrel alone.12 The significant reduction in TRAP-induced platelet activation suggests RSNO 
may act via elevation of cGMP, as shownpreviously.42 
 
Measurement of surface protein content revealed that the proportion of platelet-derived EVs 
decreased in the clopidogrel group. This specific reduction in platelet-derived EVs is in keeping with 
the hypothesis that the combined effects of RSNO and clopidogrel are responsible for the reduction in 
EV concentration seen in this study. Both cGMP and cyclic adenosine monophosphate are 
established synergistic mediators of platelet inhibition, 43 and it has previously been established that 
combined NO and clopidogrel have a synergistic effect on platelet activation.11 
 
Platelet aggregation plays a key role in the development of atherosclerosis, and anti-platelet therapy 
is well established in the treatment of CVD. Under physiological conditions, adhesion of platelets to 
the endothelium is inhibited by endogenous production of NO, highlighted by the reduced 
NO bioavailability observed in CVD states. Previous studies have also shown a reduction in platelet 
activation ex vivo following nitrate supplementation.26 These authors also showed that prevention of 
the enterosalivary bioconversion of NO3 _ toNO2 _ prevented the expected rise in plasma NO2 
_, the decrease in blood pressure and the inhibition of platelet aggregation.26 
 
This study highlights the ability of a simple dietary intervention, in combination with clopidogrel, to 
reduce platelet activation, as well as circulating, pro-coagulant EVs in a CVD cohort. Thus, inorganic 
nitrates are capable of increasing patient responsiveness to clopidogrel. High on-treatment platelet 
reactivity is common in approximately 15 to 40% of patients prescribed clopidogrel.44 As formation of 
clopidogrel– SNO does not require activation of the pro-drug, all patients on clopidogrel would benefit 
increases in NO bioavailability, regardless of their clopidogrel metabolism. This may explain the 
various pleiotropic effects of clopidogrel that have been observed in recent studies.8 Ultimately, 
reducing the circulating, pro-coagulant EVs in CAD patients offers a new approach to moderating of 
the risk of thrombus formation and thus a myocardial infarction. This may also be of therapeutic 
interest in other CVD cohorts, as well as cancer patients, where cancer-associated thrombosis is the 
second leading cause of death.45 
 
This study has several limitations. First, despite the robust design of a placebo-controlled, double-
blind, crossover study, the small sample size of groups (n ¼ 10), powered to enable the study to 
detect significant changes in EV concentration, limits the overall power of the study in terms of 
association between factors. Thus, there are several nonsignificant trends which may have been 
significant in a larger sample population. Although not statistically significant, a trend to decreased 
platelet aggregation was observed in patients not receiving clopidogrel. A large-scale study will 
be required to fully investigate the effect of NO3 _ alone on platelets; however, this observation was 
not accompanied by a decrease in EV or increase in RSNO. Second, the concentration of circulating 
RSNO attained in patients receiving clopidogrel is considerably lower than those used in in vitro 
models. The intentions of the in vitro studies were not to mimic the in vivo concentrations of these 
molecules, but rather a proof-of-principle to demonstrate the capability of clopidogrel–SNO to inhibit 
platelet EV release in response to addition of a pharmacological agent. The authors also recognize 
small differences in both cardiovascular risk factors and medications between the naïve and 
clopidogrel groups, rendering it difficult to conclude that differences in outcomes seen in this study are 
due to clopidogrel treatment or other potential confounding factors. Patients in both groups had been 
prescribed PPIs, which may have affected increased pH in the stomach toward neutrality and thus 
may have interfered with clopidogrel–SNO formation. However, it is important to note that PPI raises 
stomach pH from approximately 2 to 3 to about 4 to 6.46–48 At this pH, RSNO formation is only 
marginally reduced, as shown previously.17 Furthermore, nitrate supplementation was given about 
1 hour after patients took their clopidogrel. This may not be optimal timing to facilitate the formation of 
clopidogrel– SNO. However, studies have highlighted the delayed transit of clopidogrel in CVD 
patients, visualizing intact tablets within the stomach 1.5 to 2 hours following ingestion.49 Thus, 
significant levels of clopidogrel would remain in the stomach while simultaneous increases in nitrite 
within the stomach also occur, facilitating clopidogrel–SNO formation. Comparisons between naïve 
and clopidogrel groups showed a similar reduction in platelet aggregation, EV concentration and EV 
surface markers following nitrate supplementation. Thus, due to the lack of RSNO produced by the 
naïve group, it is unlikely that the formation of RSNO is the sole mechanism responsible for the 
beneficial effects of nitrite. Finally, our study investigated the acute effects of a single nitrate 
supplement. Future studies should address the effect of chronic nitrate supplementation on EV 
populations in relation to RSNO and platelet activity in patients. 
 
In summary, this study shows that acute nitrate supplementation can reduce platelet-derived EVs and 
residual platelet activity only in patient’s receiving clopidogrel and nitrate concomitantly. Increases in 
plasma RSNO are observed only in these patients. These results suggest that dietary NO3 
_ supplementation could provide an additional adjunct to platelet inhibition with clopidogrel in patients 
at risk from CVD. Medical Biochemistry, UHW, for performing the biochemical measurements on the 
patient samples. Finally, the authors would like to thank the nursing team for overseeing the care of 
the patients at both the cardiology outpatients’ clinic and the cardiac day care unit at the 
University Hospital of Wales. 
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